Dianthus Therapeutics Inc

NASDAQ:DNTH

20.06

-0.55 (-2.67%)

4:46:54 PM EDT: $20.15 +0.09 (+0.45%)

Market Cap (Intraday)	627.91M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.86 Million
Adjusted EPS	-$0.87

See more estimates

10-Day MA	$19.26
50-Day MA	$18.85
200-Day MA	$22.27

See more pivots

Dianthus Therapeutics Inc Stock, NASDAQ:DNTH

7 Times Square, 43rd Floor, New York, New York 10036

United States of America

Phone: +1.929.999.4055

Number of Employees: 78

http://dianthustx.com

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.